H.C. Wainwright analyst Jason Kolbert started Coherus Biosciences (CHRS) with a Buy rating and $28 price target. The analyst expects approval of the company's Udencya in both the U.S. and Europe this year. His confidence level is driven by a positive recommendation from the European Committee for Medicinal Products for Human Use in July for marketing authorization of Udencya, a biosimilar compound targeting febrile neutropenia. Coherus announced that the committee reviewed all the new immunogenicity data that were required for the U.S. re-submission too, so the EU recommendation for approval adds a measure of confidence in support of U.S. approval, Kolbert tells investors in a research note. A year-end approval should position Udencya as the second biosimilar in the $4B U.S. marketplace behind Mylan (MYL), which should be launching its product following approval in June, the analyst adds.